288 related articles for article (PubMed ID: 33786727)
1. Pharmacoinformatics-based identification of transmembrane protease serine-2 inhibitors from Morus Alba as SARS-CoV-2 cell entry inhibitors.
Shakya A; Chikhale RV; Bhat HR; Alasmary FA; Almutairi TM; Ghosh SK; Alhajri HM; Alissa SA; Nagar S; Islam MA
Mol Divers; 2022 Feb; 26(1):265-278. PubMed ID: 33786727
[TBL] [Abstract][Full Text] [Related]
2. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
[TBL] [Abstract][Full Text] [Related]
3. Molecular docking analysis reveals the functional inhibitory effect of Genistein and Quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein.
Manjunathan R; Periyaswami V; Mitra K; Rosita AS; Pandya M; Selvaraj J; Ravi L; Devarajan N; Doble M
BMC Bioinformatics; 2022 May; 23(1):180. PubMed ID: 35578172
[TBL] [Abstract][Full Text] [Related]
4. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
5. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.
Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606
[TBL] [Abstract][Full Text] [Related]
6. Prevention of SARS-CoV-2 cell entry: insight from
Gyebi GA; Adegunloye AP; Ibrahim IM; Ogunyemi OM; Afolabi SO; Ogunro OB
J Biomol Struct Dyn; 2022 Mar; 40(5):2121-2145. PubMed ID: 33089728
[TBL] [Abstract][Full Text] [Related]
7. In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2).
Barge S; Jade D; Gosavi G; Talukdar NC; Borah J
Eur J Pharm Sci; 2021 Jul; 162():105820. PubMed ID: 33775827
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoinformatics approach based identification of potential Nsp15 endoribonuclease modulators for SARS-CoV-2 inhibition.
Savale RU; Bhowmick S; Osman SM; Alasmary FA; Almutairi TM; Abdullah DS; Patil PC; Islam MA
Arch Biochem Biophys; 2021 Mar; 700():108771. PubMed ID: 33485847
[TBL] [Abstract][Full Text] [Related]
9. In Silico Screening of Novel TMPRSS2 Inhibitors for Treatment of COVID-19.
Wang S; Fang X; Wang Y
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807455
[TBL] [Abstract][Full Text] [Related]
10. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
[TBL] [Abstract][Full Text] [Related]
11. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
[TBL] [Abstract][Full Text] [Related]
12. Identification of naphthyridine and quinoline derivatives as potential Nsp16-Nsp10 inhibitors: a pharmacoinformatics study.
Aldahham BJM; Al-Khafaji K; Saleh MY; Abdelhakem AM; Alanazi AM; Islam MA
J Biomol Struct Dyn; 2022 Jun; 40(9):3899-3906. PubMed ID: 33252031
[TBL] [Abstract][Full Text] [Related]
13. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.
Kumar V; Dhanjal JK; Bhargava P; Kaul A; Wang J; Zhang H; Kaul SC; Wadhwa R; Sundar D
J Biomol Struct Dyn; 2022 Jan; 40(1):1-13. PubMed ID: 32469279
[TBL] [Abstract][Full Text] [Related]
14. In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity.
Fujimoto KJ; Hobbs DCF; Umeda M; Nagata A; Yamaguchi R; Sato Y; Sato A; Ohmatsu K; Ooi T; Yanai T; Kimura H; Murata T
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215982
[TBL] [Abstract][Full Text] [Related]
15.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
16. Identification of potential anti-TMPRSS2 natural products through homology modelling, virtual screening and molecular dynamics simulation studies.
Chikhale RV; Gupta VK; Eldesoky GE; Wabaidur SM; Patil SA; Islam MA
J Biomol Struct Dyn; 2020 Aug; ():1-16. PubMed ID: 32741259
[TBL] [Abstract][Full Text] [Related]
17. The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19.
Mantzourani C; Vasilakaki S; Gerogianni VE; Kokotos G
Expert Opin Drug Discov; 2022 Mar; 17(3):231-246. PubMed ID: 35072549
[TBL] [Abstract][Full Text] [Related]
18. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
19. Highlights in TMPRSS2 inhibition mechanism with guanidine derivatives approved drugs for COVID-19 treatment.
Tachoua W; Kabrine M; Mushtaq M; Selmi A; Ul-Haq Z
J Biomol Struct Dyn; 2023; 41(22):12908-12922. PubMed ID: 36709428
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel TMPRSS2 inhibitors against SARS-CoV-2 infection: a structure-based virtual screening and molecular dynamics study.
Manandhar S; Pai KSR; Krishnamurthy PT; Kiran AVVVR; Kumari GK
Struct Chem; 2022; 33(5):1529-1541. PubMed ID: 35345416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]